

ICPE EXHIBITORS AND SPONSORS

The International Society for Pharmacoepidemiology (ISPE) gratefully acknowledges the generous support of the following organizations and institutions. Their contributions and memberships helped to enhance the scientific program content and increase attendance at the ICPE 2006. *Thank you.*

EXHIBITORS

Charles River Laboratories Clinical Services
DrugLogic
GlaxoSmithKline
GPRD
i3 Drug Safety
IPCI Erasmus University Medical Center
John Wiley & Sons
MedTel Outcomes, LLC
PharmIdeas Research
PHARMO Institute
Phase Forward/Lincoln Technologies
RTI Health Solutions
Sentrx
Uniform Data System
United BioSource Corporation
The Uppsala Monitoring Centre
Wolters Kluwer Health, Adis

ACADEMIC SHOWCASE / WELCOME RECEPTION SPONSORS

Boston Collaborative Drug Surveillance Program,
Boston University
Center for Clinical Epidemiology & Biostatistics,
University of Pennsylvania School of Medicine
Drug Safety Research Unit
Pharmacoepidemiology and Therapeutics Program,
Utrecht Institute for Pharmaceutical Sciences (UIPS)
Pharmacy Practice & Administration Division, College of
Pharmacy, University of Texas at Austin
Slope Epidemiology Center, Boston University
The Pharmaceutical Health Services Research Graduate
Program at the University of Maryland, Baltimore
School of Pharmacy

ANNUAL MEETING SPONSORS

◀ DIAMOND: \$25,000

- i3 Drug Safety

◀ PLATINUM: \$12,000

- John Wiley & Sons
- Novartis
- Pfizer

◀ GOLD: \$6,000

- Amgen
- Eli Lilly and Company
- GlaxoSmithKline
- Merck & Co., Inc. — USA
- RTI Health Solutions
- Procter & Gamble
- United BioSource Corporation
- Wyeth Research

◀ SILVER: \$3,000

- Boehringer Ingelheim Pharmaceuticals
- Genzyme

◀ BRONZE: \$1,500

- Allergan
- GPRD
- HealthCore
- Outcome

IN THIS PROGRAM:

22nd ICPE Agenda	
Wednesday.....	7
Thursday.....	8
Friday.....	9
Saturday.....	16
Sunday.....	24
22nd ICPE Posters	
Poster Presentation Guidelines.....	30
Poster Session A.....	31
Poster Session B.....	39
Poster Session C.....	45
22nd ICPE Abstract Index	
Abstract Index.....	52

AGENDA | Wednesday, August 23

11:00-Noon

◀ ISPE Finance Committee (Hotel Vila Gale Opera)

Noon-1:00PM

◀ Orientation Session for
New ISPE Board Members (Hotel Vila Gale Opera)

Noon-5:30PM

◀ Registration (Registration Desk/Ground Floor/Congress Centre)

1:00-5:30PM

◀ ISPE Board of Directors Meeting (Hotel Vila Gale Opera)

22nd

ICPE

– Pharmacoepidemiology
for Public Health

August 24-27, 2006

Lisboa Congress Centre Lisbon, Portugal

PRE-CONFERENCE EDUCATIONAL SESSION

1:30-5:30PM

◀ Speakers Ready Room/AV (Rooms 1.09 + 1.14)

◀ Introduction to Pharmacoepidemiology

(AUD 3 & 4)

Registration required; included as part of full meeting registration.

Chair: **Andrew McAfee**

Andrew Bate, *Spontaneous Reporting*

Andrew McAfee, *Cohort Studies*

Michael Lewis, *FISPE, Case-Control Studies*

Jacques LeLorier, *FISPE, Confounding by Indication*

7:30-10:00PM

◀ ISPE Board of Directors Dinner

(By invitation)

Badges

All attendees at ICPE 2006 must wear their name badges to ALL events. A badge will be needed for admission to meeting related functions such as scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets will be required.

Badge Legend

Student – Yellow
New Member – Blue Dot
One Day Attendee – Red

Room Legend

AUD = Auditorium
PAV = Pavilion

FUTURE MEETINGS

2006

First Asian International Society for
Pharmacoepidemiology Conference *combined with*
the Third China Shanghai International Conference
on Rational Drug Use and Pharmacoepidemiology
September 26-29, 2006
Shanghai & Lu Mountain, Jiangxi province, China

2007

ISPE Mid-Year Meeting

April 21-22, 2007

Hotel NH Grand Hotel Krasnapolsky
Amsterdam, The Netherlands

(Meeting held in conjunction with the
Pharmaceutical Sciences World Congress)

Saturday, April 21

8:30-12:30pm Introduction to Pharmacoepidemiology

12:30-5:30pm ISPE Board of Directors Meeting

Sunday, April 22

8:30-1:30pm Advanced Topics in Pharmacoepidemiology

1:30-5:30pm ISPE Scientific Program Committee –2007

Monday, April 23

ISPE Contributed Symposium at the PSWC

RAI Congress Centre

www.fip.org/PSWC

23rd ICPE

August 19-22, 2007

Quebec City Convention Centre

Quebec City, Quebec, Canada

2008

ISPE Mid-Year Meeting

April TBD, 2008

Boston, Massachusetts, USA

24th ICPE

August TBD

Copenhagen, Denmark

2009

ISPE Mid-Year Meeting

April, TBD

Stockholm, Sweden

25th ICPE

Providence, Rhode Island, USA

Visit the ISPE website,
www.pharmacoepi.org,
for meeting updates and
information.

AGENDA | Thursday, August 24

8:00-6:00PM

◀ **Registration** (Registration Desk/Ground Floor/Congress Centre)

8:00-5:00PM

◀ **Speakers Ready Room/AV** (Rooms 1.09 + 1.14)

PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30-Noon

◀ **Introduction to Therapeutic Risk Management: Evaluating the Effectiveness of Risk Management Programs** (AUD 3 & 4)

* Admission by ticket only. Tickets will be included in registration for those who registered for this session.

Elizabeth Andrews, FISPE, *Overview of Risk Management and the Role of Evaluation*

Javier Cid, *Selected Examples of Risk Management Programs and Evaluation*

Judith Jones, FISPE, *Workshop for Participants to Develop an Evaluation Plan*

8:30 - Noon

◀ **Skills Workshop – Students Only*** (Room 3A)

* Registration required; included as part of full meeting registration

- *How to Design an Effective Presentation for Your Internal and External Stakeholders* [649]

Shubh L Sethi, Matthew W Reynolds. (United States)

- *How Did I Get Here?*

Roundtable discussion of career opportunities within pharmacoepidemiology

Moderator: *Marieke Schoonen*

Panelists:

Peter Egger, European Industry Perspective

Tjeerd van Staa, European Regulatory Agency Perspective

Stephen J. Evans, Academic Perspective

TBA, Consulting Perspective

Noon - 1:30PM

◀ **Lunch – on your own** (available at Congress Centre)

Noon-1:30PM

◀ **ISPE Education Committee** (Room 1.05)

Noon-1:30PM

◀ **Orientation to ISPE – New Members/Student Prize Winners/Scholarship Recipients** (Espaço Tejo Restaurant/First Floor/Congress Centre)

Noon - 5:00PM

◀ **Exhibitor Move-in** (PAV 5)

PRE-CONFERENCE EDUCATIONAL SESSION

1:30-5:30PM

◀ **Advanced Topics in Pharmacoepidemiology** (AUD 3 & 4)

* Admission by ticket only. Tickets will be included in registration packet for those who registered for this session.

Chair: *Sebastian Schneeweiss, FISPE*

Larry Lynd, *Methods in Quantitative Benefit-Risk Assessment*

June Raine, *Use of Pharmacoepidemiologic Data in Regulatory Decision Making*

John Ioannidis, *Meta-Analysis of Studies on the Safety of Medications*

Julia Kirchheiner, *CYP Polymorphisms and Implications for Pharmacoepidemiology*

5:00-6:00PM

◀ **Academic Showcase Set-up**

(Foyer- First Floor)

6:30-8:00PM

◀ **Academic Showcase/**

Welcome Reception (Foyer – First Floor)

Admission by badge or ticket. *Cash bar*

- **Welcome**

Ana Paula Martins, Local Host Committee

Bert Leufkens, FISPE, Chair, Scientific Program Committee

Sean Hennessy, FISPE, ISPE President

- **Academic Programs** (as of July 25, 2006)

Boston Collaborative Drug Surveillance Program,
Boston University School of Medicine

Center for Clinical Epidemiology & Biostatistics,
University of Pennsylvania School of Medicine

College of Pharmacy, University of Texas

Drug Safety Research Unit

Pharmacoepidemiology and Therapeutics

Program, Utrecht Institute for Pharmaceutical
Sciences (UIPS), University of Utrecht

Slone Epidemiology Center, Boston University

The Pharmaceutical Health Services Research
Graduate Program at the University of
Maryland, Baltimore School of Pharmacy

AGENDA | Friday, August 25

8:00-9:00AM

◀ Poster Session A Set-up (PAV 4)

8:00-5:00PM

◀ Exhibits (PAV 5)

◀ Speakers Ready Room/AV (Rooms 1.09 + 1.14)

8:00-6:00PM

◀ Registration

(Registration Desk/Ground Floor/Congress Centre)

9:00-10:30AM

OPENING SESSION (AUD 1)

◀ Welcome

Bert Leufkens, FISPE, Chair, Scientific Program Committee

Vasco de Jesus Maria, Chair, Local Host Committee

◀ Presidential Address

Sean Hennessy, FISPE, ISPE President

◀ Keynote Address


Richard Laing, WHO Department of Policy and Standards for Medicines, Geneva Switzerland
Pharmacoepidemiology for Public Health

10:30-11:00AM

◀ Break/Posters/
Exhibits (PAV 4/5)

*Sponsored by
RTI Health Solutions*

— *Pharmacoepidemiology for Public Health* —



RTI HEALTH SOLUTIONS®



THE DATABASE CHALLENGE

Rely on our experience to select the right databases for your epidemiological studies.

Contact

Research Triangle Park, NC, USA
US 1.800.282.3011/1.919.541.6000 x1541

Manchester, UK
UK 44(0)161.232.3400

www.rtihs.org
rtihealthsolutions@rti.org



• Visit RTI Health Solutions' exhibit booth to learn how we can help you design and implement your database studies.

Test your knowledge of European databases and win a prize.

LEADING RESEARCH...

MEASURES THAT COUNT

11:00-12:30PM

CONCURRENT SESSIONS

◀ Risk Assessment: Contributed Papers (AUD 2)

Moderators: *Byung-Joo Park, FISPE & Corinne de Vries*

11:00AM

Corticosteroids and the Risk of Atrial Fibrillation [2]

Cornelis S van der Hooft, Jan Heeringa, Guy G Brusselle, Albert Hofman, Jacqueline C Witteman, Herre Kingma, Miriam C Sturkenboom, Bruno H Stricker. (Netherlands)

11:15AM

Increased Risks of End-Stage Renal Disease Associated with Prescribed Chinese Herb Medicines: A Follow-Up of the Representative 200,000 People in Taiwan, 1997-2002 [3]

Ming-Nan Lai, Jung-Nien Lai, Pau-Chung Chen, Wei-Lum Tseng, Ya-Yin Chen, Jung-Der Wang. (Taiwan)

11:30AM

Comparison of Incidence of Hypoglycemia in Patients with Diabetes Treated with Rapid-Acting Lispro vs Short-Acting Soluble Insulin by General Practitioners – GPRD 1999-2001 [4]

Mark L Ma, Meng Tan, Kenneth Hornbuckle. (United States)

11:45AM

Angiotensin Converting Enzyme – Inhibitors and Angiotensin II Receptor Antagonists and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study [5]

Christiane Gasse, Jacob Jacobsen, Mette Nørgaard, Henrik T Sørensen, Søren P Johnsen. (Denmark)

12:00PM

Oral Glucocorticoids and Risk of Suicide: A Cohort Study in the General Practice Research Database [6]

Patrick C Souverein, Niels Speksnijder, Tjeerd P van Staa, Berend Olivier, Toine CG Egberts, Hubert GM Leufkens. (Netherlands)

12:15PM

Prescription of beta-Blockers in Patients with Advanced Heart Failure and Preserved Left Ventricular Ejection Fraction. Implications for Survival [7]

Daniela Dobre, Dirk J Van Veldhuizen, Mike JL DeJongste, Carolein Lucas, Ger Cleuren, Robbert Sanderman, Adelita V Ranchor, Flora M Haaijer-Ruskamp. (Netherlands)

◀ SYMPOSIUM: Methods of Therapeutic Benefit-Risk Assessment [1] (AUD 1)

Y Moride, L Lynd, L Abenheim, N Moore, X Kurz, C Hartford. (Canada)

◀ WORKSHOP: Prescribing Quality Indicators Based on Administrative Data: Grasping the Essence or Scratching the Surface? [20] (AUD 3)

B Wettermark, M Andersen, V Vlahovic-Palcevski, R Vander Stichele, F Haaijer-Ruskamp, P Mol. (Netherlands)

◀ WORKSHOP: Designed Delays vs Rigorous Pragmatic Trials: How Much Should We Allow the Gold Standard of Evidence To Be Tarnished? [21] (AUD 4)

Malcolm Maclure, Colin Dormuth, Sebastian Schneeweiss, Tom MacDonald. (United States)

◀ Birth Defects: Contributed Papers (AUD 6)

Moderators: *Abraham Hartzema, FISPE & Filipa Costa*

11:00AM

Late Pregnancy Use of Non-Steroidal Anti-Inflammatory Drugs and Risk for Persistent Pulmonary Hypertension of the Newborn [8]

Sonia Hernández-Díaz, Martha M Werler, Carol Louik, Linda J Van Marter, Allen A Mitchell. (United States)

11:15AM

Risk of Congenital Malformations in Pregnant Users of Non-Steroidal Anti-Inflammatory Drugs [9]

Benjamin D Ofori, Driss Oraichi, Anick Berard. (Canada)

11:30AM

Exposure to Mirtazapine during Pregnancy: A Prospective Comparative Study of Birth Outcomes [10]

Josephine Djulus, Gideon Koren, Thomas Einarson, Lynda Wilton, Saad Shakir, Orna Diav-Citrin, Deborah Kennedy, Sharon Lavigne, Marco De Santis, Adrienne Einarson. (Canada)

11:45AM

Increase of Antidepressants' Use in Pregnancy in the Netherlands [11]

Marian K Bakker, Paul B van den Berg, Pieterneel Kolling, Lolkje TW de Jong-van den Berg. (Netherlands)

12:00PM

Paroxetine in the First Trimester of Pregnancy and the Prevalence of Congenital Malformations [12]

J Alexander Cole, Eva W Ng, Sara A Ephross, Irene S Cosmatos, Alexander M Walker. (United States)

12:15PM

Antibiotics Potentially Used in Response to Bioterrorism and Major Congenital Malformations [13]

William O Cooper, Sonia Hernandez-Diaz, Patrick G Arbogast, Wayne A Ray. (United States)

◀ Respiratory Outcomes: Contributed Papers (AUD 8)

Moderators: *Jose Marinho Falcao & Keith Beard, FIPSE*

11:00AM

Annual Influenza Vaccination in Community Dwelling Elderly and the Risk of Lower Respiratory Tract Infections or Pneumonia [14]

Bettie CG Voordouw, Miriam CJM Sturkenboom, Jeanne P Dieleman, Theo Stijnen, Johan van der Lei, Bruno HCh Stricker. (Netherlands)

11:15AM

The Control and Severity of Asthma during Pregnancy and the Incidence of Asthma in the Offspring [15]

Marie-Josée Martel, Evelyne Rey, Marie-France Beauchesne, Jean-Luc Malo, Sylvie Perreault, Amelie Forget, Lucie Blais. (Canada)

11:30AM

Assessing the Time-Dependency Nature of Comorbidity Influence in COPD [16]

Victor A Kiri, James Oyee. (United Kingdom)

11:45AM

Effectiveness of Combination Therapy in Asthma [17]

Lucie Blais, Catherine Lemièrre, Claudine Marceau, Sylvie Perreault, Djamal Berbiche. (Canada)

12:00PM

Use of beta-2 Agonists and Risk of Hip/Femur Fracture: Associations with Daily and Cumulative Dose in a Population-Based Case-Control Study [18]

Frank de Vries, Sander Pouwels, Madelon Bracke, Jan-Willem Lammers, Bert Leufkens, Mira Zuidgeest, Tjeerd van Staa. (Netherlands)

12:15PM

Theophyllines, Long-Acting b2-Agonists and Inhaled Corticosteroids and the Risk of Mortality among Patients with Chronic Obstructive Pulmonary Disease [19]

Marie-Christyne Cyr, Marie-France Beauchesne, Catherine Lemièrre, Lucie Blais. (Canada)

AGENDA | Friday, August 25

12:30 - 2:00PM

◀ Lunch/Poster Session A/Exhibits (PAV 4/5)

◀ EuroDURG General Assembly (AUD 2)

◀ ISPE Committee/Council Meetings

Lunches will be available in meeting rooms.

*Open to all participants.

◀ Public Policy Committee (Room 1.08)

◀ Student Council (Room 1.07) *All students invited to attend.

◀ Public Relations Committee (Room 1.06)

◀ Bylaws & Policies Committee (Room 1.05)

◀ Fellowship & Awards Committee (Room 1.04)

*Abstract Submission Deadline:
February 16, 2007*

**23rd International Conference on •
Pharmacoepidemiology & Therapeutic ••
Risk Management •••**

August 19-22, 2007
Quebec City
Convention Centre

*Quebec City,
Quebec, Canada*

The online abstract submission site •
will be active by mid-December 2006 ••
visit www.pharmacoepi.org •••

2:00 - 3:30PM

CONCURRENT SESSIONS

◀ SYMPOSIUM: Control of Unmeasured Confounding [22]

(AUD 1)

Til Stürmer, Jay S Kaufman, Alan Brookhart, Michal Abrahamovicz, Robert J Glynn, Kenneth J Rothman. (United States)

◀ Risk Management: Contributed Papers (AUD 2)

Moderators: Stephen J.W. Evans & Priya Bahri

2:00PM

Adverse Drug Reactions in Children: A Multicenter Study in Italy [23]

Francesca Menniti-Ippolito, Roberto Da Cas, Monica Bolli, Annalisa Capuano, Giuseppe Traversa. The Multicenter Study Group on Adverse Drug Reactions in Children. (Italy)

2:15PM

Prenatal Testing Prior to Enrollment in Pregnancy Exposure Registries [24]

Susan Roberts, Deborah Covington, Peggy Doi. (United States)

2:30PM

An Evaluation of a Sticker-Based RMP for Isotretinoin [25]

Carla M Van Bennekom, Allen A Mitchell. (United States)

2:45PM

No Increased Risk of Abdominal or Pelvic Surgery Associated with Tegaserod Exposure: The Zelnorm™ Epidemiological Study [26]

John D Seeger, Sherry Quinn, Fabio Lievano, Elena Rivero, David L Earnest, Michael Shetzline, William Holden, Alexander M Walker. (United States)

3:00PM

Safety-Related Drug Labeling Changes in the United States and Germany [27]

Edeltraut Garbe, René Schade, Frank Andersohn. (Germany)

3:15PM

Does Risk Communication Have a Direct Impact in the Overall Pharmacovigilance Activities? [28]

M Arriegas, F Bragança, R Carmona, A Pêgo, P Roque, J Silva, I Sobral. (Portugal)

◀ Workshop: Trust and Transparency: How Much Is Needed?

[41] (AUD 3)

Nicholas D Moore, Elisabeth Loupi, Brian Edwards, Kees VanGrootheest. (France)

◀ Workshop: Methodologies and Platforms for Policy Evaluation of Pharmaceutical Interventions [42] (AUD 4)

Pieter Stolk, Sebastian Schneeweiss, Robert H Vander Stichele, Eibert R Heerdink. (Netherlands)

◀ Psychotropics in Children:

Contributed Papers (AUD 6)

Moderators: *Adrienne Einarson & Emilio Sanz*

2:00PM

Psychotropic Medication Use among Publicly Insured U.S. Youth [29]

Satish C Valluri, Anthony Kouzis, Julie M Zito, James F Gardner, James Korelitz, James Bethel, Tamar Lasky, Russell A Gerber, Daniel J Safer. (United States)

2:15PM

National Trends in the Diagnosis of Attention-Deficit/Hyperactivity Disorder and Use of Stimulants among Children in the United States, 1993-2003 [30]

Sengwee Toh. (United States)

* *Student Award – Best Drug Utilization Abstract*

2:30PM

Drug Utilization Study of Methylphenidate, Dexamfetamine and Atomoxetine in Patients Aged 15-21 Years in UK Primary Care Using the General Practice Research Database (GPRD) [31]

Suzanne McCarthy, Macey Murray, Ian Wong. (United Kingdom)

2:45PM

Stimulant Utilization in Children and Adolescents in 4 Countries [32]

Julie M Zito, Daniel J Safer, Lolkje TW deJong-vandenBerg, Jorg M Fegert, Katrin Janhsen, Corinne S de Vries, Gerd Glaeske. (United States)

3:00PM

Effect of Government Regulatory Changes on SSRI Prescriptions in Children [33]

Benji T Kurian, Patrick G Arbogast, Wayne A Ray, D C Fuchs, William O Cooper. (United States)

3:15PM

Antidepressant Use among Children and Adolescent in Finland: A Register- Linkage Study, 1994-2003 [34]

Sinikka Sihvo, Tiina Sevon, Jari Haukka, Elina Hemminki, Ilmo Keskimaki, Sonja Lumme, Alison McCallum, Kristian Wahlbeck. (Finland)

◀ Genes and Biologicals: Contributed Papers (AUD 8)

Moderators: *Henrique de Barros & Joanna F. Haas*

2:00PM

Diuretic-Gene Interactions and the Risk of Myocardial Infarction and Stroke [35]

Hedi Schelleman, Olaf H Klungel, Jacqueline CM Witteman, Cornelia M van Duijn, Albert Hofman, Monique MB Breteler, Anthonius de Boer, Bruno HCh Stricker. (Netherlands)

2:15PM

Association between CV Outcomes, Diuretic Use and the α -Adducin Gene; Results from the International Verapamil SR-Trandolapril Study (INVEST) [36]

Tobias Gerhard, Yan Gong, Amber L Beitelshees, Rhonda M Cooper-DeHoff, Julie A Johnson. (United States)

2:30PM

Non-Oncologic Use of Human Recombinant Erythropoietin in Hospitalized Patients [37]

Charles A Morris, Michael A Fischer, Wolfgang C Winkelmayr, Jerry Avorn. (United States)

2:45PM

ABCBI G2677T/A and C3435T Polymorphisms and the Risk of Drug Induced Acute Agranulocytosis [38]

Frank Andersohn, Elisabeth Bronder, Andreas Klimpel, Edeltraut Garbe. (Germany)

3:00PM

Tumor Necrosis Factor- α Antagonist Use and Cancer in Patients with Rheumatoid Arthritis [39]

Soko Setoguchi, Daniel H Solomon, Michael E Weinblatt, Jeffrey N Katz, Jerry Avorn, Robert J Glynn, E Francis Cook, Greg Carney, Sebastian Schneeweiss. (United States)

3:15PM

Absence of an Interaction between the Angiotensin Converting Enzyme (ACE) Insertion-Deletion Polymorphism and Pravastatin on Cardiovascular Disease in High-Risk Hypertensives: The GenHAT Study [40]

Anke H Maitland-van der Zee, Eric Boerwinkle, Donna K Arnett, Barry R Davis, Catherine Leidencker-Foster, Michael B Miller, Olaf H Klungel, Charles E Ford, John E Eckfeldt. (Netherlands)

3:30-4:00PM

◀ Break/Posters/Exhibits (PAV 4/5)

4:00 – 5:30PM

CONCURRENT SESSIONS

◀ SYMPOSIUM: Clinical Trial Simulation in Pharmacoepidemiology [43] (AUD 1)

Sonia Hernández-Díaz, Wayne A Ray, Alexander M Walker, Miguel A Hernán. (United States)

◀ Pharmacovigilance: Contributed Papers (AUD 2)

Moderators: *Bruno Stricker & Marques Batel*

4:00PM

Data Mining in the US FDA Adverse Event Reporting System (AERS): Depression/Suicidality and Unexpected Adverse Events with Anti Obesity Drugs [44]

F Patrick DeLisle, Kenneth Hornbuckle, Rebecca Noel. (United States)

4:15PM

Severe Necrotising Soft Tissue Infections and Necrotizing Fasciitis and NSAIDs: A Study in the French Pharmacovigilance Database [45]

Christelle Souyri, Pascale Olivier, Maryse Lapeyre-Mestre. (France)

4:30PM

Intervention To Improve Adverse Drug Event Reporting: A Cluster-Randomized Trial among Portuguese Physicians [46]

Teresa Herdeiro, Adolfo Figueiras, Manuela Pinto, Inês Vaz, Jorge Polónia. (Portugal)

4:45PM

A New Automatic Signal Detection Method in Pharmacovigilance: A Bayesian Multiple Comparisons Setting [47]

Ismail Ahmed, Françoise Haramburu, Annie Fourier, Frantz Thiessard, Bernard Bégaud, Pascale Tubert-Bitter. (France)

5:00PM

Evolution of Hospitalizations Related to Poisoning Events in Portugal [48]

José P Guerreiro, José Giria, Filipa Costa, Ermelindo Fontes, Ana C Miranda. (Portugal)

5:15PM

Are Inappropriate Medications the Major Cause of Adverse Drug Reactions in the Elderly? [49]

Marie-Laure Laroche, Jean-Pierre Charmes, Louis Merle. (France)

◀ WORKSHOP: Applications of Standardised MedDRA Queries (SMQs) in Drug Safety and Pharmacoepidemiology [62] (AUD 3)

Gottfried Kreuz, Judith K Jones, Norbert Paeschke, Sabine Luik. (United States)

◀ WORKSHOP: Pharmacoepidemiology and Biotechnology Products [63] (AUD 4)

Joanna F Haas, Rhonda L Bohn, Kathryn Starzyk, Stella Blackburn, Bettie Voordouw, John Ferguson, Nancy Dreyer (United States)

◀ Women's Health: Contributed Papers (AUD 6)

Moderators: *Saad Shakir & Annlouise Assaf*

4:00PM

Natural History of Newly Diagnosed Patients with Venous Thromboembolism [50]

Consuelo Huerta, Mary-Ann Wallander, Saga Johansson, García Rodriguez Luis Alberto. (Spain)

4:15PM

The Risk of Venous Thromboembolism (VTE) in Oral Contraceptives: A New Lesson [51]

Lothar AJ Heinemann, Anita Assmann, Juergen C Dinger. (Germany)

4:30PM

Factors Influencing Return to Fertility after Use of Oral Contraceptives [52]

Ilka Schellschmidt, Do Minh Thai, Sabine Moehner, Juergen C Dinger. (Germany)

4:45PM

Cyproterone Acetate + Ethinylloestradiol and the Risk of Depression [53]

Helen E Seaman, Julia Snowball, Corinne S de Vries. (United Kingdom)

5:00PM

Hormone Therapy Re-Initiation and First-Time Initiation by Type, Dose and Route, after the Women's Health Initiative [54]

Katherine M Newton, Diana SM Buist, Onchee Yu, Cynthia L Hartsfield, Susan E Andrade, Feifei Wei, Maureen T Connelly, K Arnold Chan. (United States)

5:15PM

The European Active Surveillance Study on Oral Contraceptives (EURAS-OC): Final Results after More Than 130,000 WY of Observation [55]

Juergen C Dinger, Anita Assmann, Lothar AJ Heinemann. (Germany)

◀ Infections/Pandemic Flu:

Contributed Papers (AUD 8)

Moderators: *Miles Braun, FISPE & Harry Seifert*

4:00PM

Evaluating Reports of Fever after Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B, Inactivated Poliovirus Vaccine Combined (DTaPHE) from the U.S. Vaccine Adverse Event Reporting System (VAERS) [56]
Soju Chang, John Iskander, Karen Farizo, M Miles Braun, Robert Ball. (United States)

4:15PM

An Evaluation of the Effects of Gatifloxacin on Glucose Homeostasis [57]
Ahunna Onyenwenyi, Almut Winterstein, Randy Hatton. (United States)

4:30PM

Antibacterial Drugs and the Risk of Infection with Methicillin Resistant Staphylococcus Aureus (MRSA) in the Community [58]
V Schneider, S Dial, J A Delaney, A Dascal, S Suissa. (Canada)

4:45PM

Anti-TNF-alpha Therapy and the Risk of Severe Bacterial Infections [59]
Sebastian Schneeweiss, Soko Setoguchi, Michael E Weinblatt, Jeffrey N Katz, Jerry Avorn, Paul E Sax, Raia Levin, Daniel H Solomon. (United States)

5:00PM

Annual Influenza Vaccination and Risk of Sudden Cardiac Death in Community Dwelling Elderly Persons [60]
Bettie CG Voordouw, Sabine SJM Straus, Miriam CJM Sturkenboom, Jeanne P Dieleman, Theo Stijnen, Johan van der Lei, Bruno HCh Stricker. (Netherlands)

5:15PM

Quinolone Use and the Risk of Community-Acquired Clostridium difficile in the United Kingdom [61]
J A Delaney, Sandra Dial, Alan N Barkun, Samy Suissa. (Canada)

5:30-6:30PM

◀ ISPE Council Meetings

* Open to all participants.

◀ Academic Council (AUD 2)

◀ Industry Council (AUD 6)

◀ Government Council (AUD 8)

◀ EuroDURG Executive Committee (Room 1.II)

6:30-8:30PM

EXTERNALLY FUNDED SYMPOSIUM*

◀ GPRD Users Group Meeting (Hotel Vila Gale Opera)

* Open to all participants. Not part of the ICPE Scientific Program.

This symposium provides an opportunity to learn about the latest developments in GPRD, including new data linkages, the new possibility of conducting randomized studies within GPRD, and a novel approach in risk-benefit assessment. A canapé reception to follow.

◀ PDS Editorial Board (Pestana Palace)

(By invitation)

7:30-10:00PM

◀ Student Social Event

Check bulletin board at Registration Desk for details.

Open to all students.

Organized by the ISPE Student Council

JOINT ISPE-EURODURG DAY

7:30-8:30AM

- ◀ **Special Interest Group – Drug Utilization** (Hotel Vila Gale Opera)
*Open to all participants.

8:00-9:00AM

- ◀ **Poster Session B Set-up** (PAV 4)

8:00-5:00PM

- ◀ **Exhibits** (PAV 5)

- ◀ **Speakers Ready Room/AV** (Room I.09 + I.14)

8:00-6:00PM

- ◀ **Registration** (Registration Desk/Ground Floor/Congress Centre)

9:00-10:30AM

PLENARY SESSION

- ◀ **Balancing Patient Safety and Pharmaceutical Innovation: Fostering the Lisbon Objectives** (AUD 1)

Moderator: *Fernard Sauer*

Vasco de Jesus Maria, *Is 'Lisbon' Still Driving the EU Medicines Policy Agenda?*

Albert van der Zeijden, *Are Patients Happy with so much Focus on Safety?*

Susana Perez-Gutthann, FISPE, *How is Industry Balancing Innovation and Patient Safety?*

10:30-11:00AM

- ◀ **Break/Posters/Exhibits** (PAV 4/ 5)

“Company of the Year”

FORBES MAGAZINE 2004

“One of the Best Places to Work in Industry”

THE SCIENTIST 2004 (ranked in the top five)

“A Top Employer in the Biotechnology and Pharmaceutical Industry”

SCIENCE MAGAZINE 2005 (ranked in the top five)

“One of the 100 Best Companies to Work for in America”

FORTUNE MAGAZINE 2006 (for the seventh time)

“One of the Top 100 Best Small Companies to Work For in the UK”

THE SUNDAY TIMES 2006

Rewarding work

For more information please email: EURD_UKcareers@amgen.com

AMGEN



I want to share my expertise.

You can at AstraZeneca. As a global pharmaceutical industry leader, AstraZeneca has created a work environment that cultivates talent and rewards success. We offer competitive compensation and benefits, a commitment to professional development, and the opportunity to be part of an exciting, dynamic workplace.

Among our many awards we have been recognized in 2005 as one of the **Top Employers** by *Science* magazine and one of the **100 Best Employers for Working Mothers** by *Working Mother* magazine. AstraZeneca embraces diversity, innovation and creativity — pushing the boundaries of conventional thought to make our ideas come to life.

To apply, please submit your resume via email to opportunities.mailbox@astrazeneca.com and reference **source code 11436635** in the Subject line.

We are an equal opportunity employer.



www.AstraZenecaCareers.com



We have the following United States based career opportunity available in our Wilmington, Delaware location.

Assoc. Director/Director/Sr. Director, Epidemiology

Working within the Medical Science group, this individual will provide epidemiology expertise for one of several therapeutic areas. Will work with senior staff on study design, analysis, data interpretation, and reporting functions related to clinical trials; ensure clinical studies operate with the highest safety standards and are in compliance with all GCP and regulatory requirements; perform in-depth epidemiological literature reviews; and initiate and monitor epidemiological research conducted by external scientific groups.

Physicians (Epidemiologists) must have two or more years of drug development experience within a related industry or in academia, significant experience designing clinical trials and interpreting results, and a comprehensive understanding of biostatistics and safety reporting. Scientists (PhD) in epidemiology should possess at least 5 years' experience as an epidemiologist in a healthcare environment and sustained productivity in epidemiological research relevant to drug discovery.

AstraZeneca 

11:00 – 12:30 PM

CONCURRENT SESSIONS

◀ ISPE-EuroDURG SYMPOSIUM (AUD 1)

Global Assessment of the Contribution of Drug Utilization Research to Public Health

Co-Chairs: *Frank May, FISPE & Robert Vander Stichele*

Speakers: **Flora Haaijer-Ruskamp**, Europe; **Richard Laing**, Developing World; **Junichi Kawakami**, Japan; **Jerry Avorn, FISPE**, US/Canada; **Lynn Weekes**, Australia

◀ Methods: Contributed Papers (AUD 2)

Moderators: *Tjeerd van Staa & Alexander M. Walker, FISPE*

11:00AM

Mixed Effect Poisson Regression with Empirical Bayes Random Effect Estimation: Application to Opioid Analgesic Abuse in the US [64]

William Irish, Meredith Smith, Jianmin Wang, Rick Dart. (United States)

11:15AM

Pharmacologic Interventions for the Prevention of Alzheimer's Disease: An Example of Reverse Protopathic Bias [65]

Linda E Levesque, JAC Delaney, Mahyar Etminan, Samy Suissa. (Canada)

11:30AM

Randomized Experiments Versus Observational Studies? The Case of Antiretroviral Therapy and AIDS [66]

Miguel A Hernan, Stephen R Cole. (United States)

11:45AM

Nested Case-Control Validation of Results of the Zelnorm™ Epidemiological Study [67]

John D Seeger, Najat Ziyadeh, Fabio Lievano, Elena Rivero, David L Earnest, Michael Shetzline, William Holden, Alexander M Walker. (United States)

12:00 PM

Stratified Case-Cohort Design in Pharmacoepidemiological Studies [68]

Akira Wakana, Kiyoshi Kubota. (Japan)

12:15PM

Risk Adjusted Sequential and Longitudinal Monitoring Drug Performance Using GPRD [69]

Mark L Ma, Kenneth Hornbuckle, Simon Voss, Xiao Yu. (United States)

◀ WORKSHOP: Willingness To Accept Risk-Benefit Tradeoffs: Pharmacoepidemiology Meets Preference Measurement [77]

(AUD 4)

F Reed Johnson, Teresa Kauf, Elizabeth B Andrews. (United States)

◀ Antipsychotics: Contributed Papers (AUD 6)

Moderators: *Antoine Egberts & Julie Zito*

11:00AM

Antipsychotic Use and the Development of Cardiovascular Conditions in the Elderly [70]

Philip S Wang, Sebastian Schneeweiss, Soko Setoguchi, Jerry Avorn, Helen Mogun, Niteesh Choudhry, M Alan Brookhart. (United States)

11:15AM

The Use of Atypical and Conventional Antipsychotics and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study [71]

Christiane Gasse, Jacob Jacobsen, Mette Nørgaard, Preben B Mortensen, Søren P Johnsen, Henrik T Sørensen. (Denmark)

11:30AM

Risk of Stroke during Treatment with Atypical and Conventional Antipsychotics: A Population-Based Study in the UK [72]

Annalisa Rubino, Stephen J Evans, Liam Smeeth. (United Kingdom)

11:45AM

Use of Antipsychotics and Risk of Hip/Femur Fractures: A Population Based Case-Control Study [73]

Sander Pouwels, Frank de Vries, Antoine CG Egberts, Bert GM Leufkens, Tjeerd P van Staa. (Netherlands)

12:00PM

Early Effects of an FDA Advisory Regarding Antipsychotics Medications on U.S. Medicaid Prior Authorization Programs [74]

Jennifer Polinski, Michael Fischer, Amber Servi, Elizabeth Robinson, Philip Wang. (United States)

12:15PM

Anti-Psychotic Drugs and the Risk of Acute Urinary Retention [75]

Katia MC Verhamme, Jeanne P Dieleman, Marc Van Wijk, Johan van der Lei, Ruud Bosch, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)

◀ **SYMPOSIUM: Increased Transparency To Improve the Credibility of Pharmacoepidemiologic Studies Submitted to Regulatory Agencies and Journals? [76] (AUD 8)**

Michael N Cook, Robert C Nelson, Sean Hennessy, Julie E Buring. (United States)

12:30-2:00PM

◀ **Lunch/Poster Session B/Exhibits**

(PAV 4/5)

12:30-2:00PM

◀ **EuroDURG Poster Walk (PAV 4)**

*Open to all participants.

◀ **ISPE Committee Meetings**

Lunches will be available in meeting rooms.

*Open to all participants.

◀ **Development (Room 1.08)**

◀ **Membership (Room 1.07)**

◀ **Global Development (Room 1.06)**

◀ **Publications (Room 1.05)**

For 100 years, patients first.

Merck is a global research-driven pharmaceutical company dedicated to putting patients first in all we do. That philosophy was first articulated by George Merck and it still guides us today.

For nearly 100 years, Merck has discovered, developed, manufactured and marketed novel medicines and vaccines that have delivered true advances in patient care for people around the world. We continue to do the same today.

As part of our ongoing commitment to patients, Merck devotes extensive efforts to get our medicines to those who need them regardless of their ability to pay for them and we make free, unbiased health information available to everyone.

For more information, visit www.merck.com

Where patients come first  **MERCK**



AGENDA | Saturday, August 26

2:00-3:30PM

ANNUAL MEETING & AWARDS CEREMONY

Open to all participants. (AUD 1)

Annual Meeting of ISPE Members

Sean Hennessy, FISPE,
ISPE President

Frank May, FISPE, *ISPE Vice President/Finance*



Induction of ISPE Fellows (FISPE)

Gerald A. Faich, FISPE, *Chair, Fellowship & Awards Committee and ISPE Immediate Past President*

• Inductees:

Syed Rizwanuddin Ahmad, FISPE

Miles Braun, FISPE

Thomas R. Einarson, FISPE

Til Stürmer, FISPE

Suzanne L. West, FISPE

Awards Ceremony

ICPE 2006

Ana Paula Martins, *Local Host Committee*

Bert Leufkens, FISPE, *Chair, 2006 Scientific Program Committee*

Student Awards

Presented by Bert Leufkens, FISPE, *Chair, 2006 Scientific Program Committee*

Best Drug Utilization Abstract: Sengwee Toh, *Harvard University School of Public Health*. National Trends in the Diagnosis of Attention Deficit/Hyperactivity Disorder and Use of Stimulants among Children in the United States

Best Methods Abstract: Linda E. Levesque, *McGill University*. Variability of Cardiovascular Risk in Observational Studies of Nonsteroidal Antiinflammatory Drugs (NSAIDs): The Role of Calendar Time Bias

Edlavitch Award: Jeroen J. Derijks, *Utrecht Institute of Pharmacoepidemiological Sciences*. The Association between Antidepressant Use and Hypoglycemia in Diabetic Patients: A Nested Case-Control Study.

ISPE-PDS Prizes

Presented by Brian L. Strom, FISPE, Regional Editor for the Americas, *Pharmacoepidemiology & Drug Safety*

Giovanni Corrao, Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials

Hilde Tobi, Small proportions: what to report for confidence

Nancy S. Breekveldt, Postma Selective prescribing of atypical antipsychotics

Dustin D. French, Benzodiazepines and injury: a risk adjusted model

Robert J. Cluxton Jr, Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio Medicaid program

ISPE Distinguished Service Award

Presented by Sean Hennessy, FISPE

- Recipient: Frank May, FISPE

ISPE Sustained Scientific Excellence Award

Presented by Gerald A. Faich, FISPE

- Recipient: Brian L. Strom, FISPE
- Address by: Brian L. Strom, FISPE

The Lessons of Experience: Selected Tidbits from a Mid-Career Academic Pharmacoepidemiologist

3:30 - 4:00PM

◀ Break/Posters/
Exhibits (PAV 4/5)



4:00 - 5:30PM

CONCURRENT SESSIONS

◀ SYMPOSIUM: How Can Prescribing Quality Indicators Improve Public Health [78] (AUD 1)

Flora M Haaijer-Ruskamp, Tony J Avery, Jerry Avorn, Bjorn Wettermark. (Netherlands)

◀ Propensity Scores: Contributed Papers (AUD 2)

Moderators: *Kenneth J. Rothman, FISPE & Alejandro Arana, FISPE*

4:00PM

The Limiting Role of the C-Statistic in the Use of Propensity Scores: Evidence from Simulation and Real Life Data [79]

Maurille A Feudjo-Tepie, Victor A Kiri. (United Kingdom)

4:15PM

Adjustment for Multiple Cardiovascular Risk Factors with a Summary Risk Score [80]

Patrick G Arbogast, Hua Ding, Wayne A Ray. (United States)

4:30PM

Estimation and Use of Propensity Scores in Case-Control and Case-Cohort Studies [81]

Roger Mansson, Sean Hennessy, Marshall M Joffe. (United States)

4:45PM

Validation of Propensity Score Matching of Ethinyl Estradiol / Drospirenone and Other Oral Contraceptive Initiators [82]

P Mona Eng, John D Seeger, Jeanne Loughlin, C Robin Clifford, Sherry Mentor, Alexander M Walker. (United States)

5:00PM

Comparison of Performance of Propensity Score Calibration (PSC) and Multiple Imputation (MI) To Control for Unmeasured Confounding Using an Internal Validation Study [83]

Til Stürmer, Sebastian Schneeweiss, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)

5:15PM

Bayesian Propensity Score Analysis for Observational Data [84]

Lawrence C McCandless, Paul Gustafson, Peter C Austin. (Canada)

◀ WORKSHOP: To “p” or Not To “p”? How Do ISPE Members Feel about p-Values and Statistical Testing: An ISPE Public Policy Forum [92] (AUD 4)

Elisabeth B Andrews, Susana Perez-Gutthann. (United States)

◀ Antidepressants: Contributed Papers (AUD 6)

Moderators: *Jan Willem van der Velden, FISPE & Thomas MacDonald, FISPE*

4:00PM

Risk of Suicide during Venlafaxine and Comparator Antidepressants Treatment [85]

Annalisa Rubino, Neil Roskell, Pat Tennis, Daniel Mines, Scott Weich, Elizabeth Andrews. (United Kingdom)

4:15PM

Tricyclic Antidepressants and the Risk of Esophagitis [86]

Eva M van Soest, Jeanne D Dieleman, Peter D Siersema, Miriam JCM Sturkenboom, Ernst J Kuipers. (Netherlands)

4:30PM

The Risk of Fractures in Patients Currently or Previously Using Lithium [87]

Ingeborg Wilting, Frank de Vries, Brahm MKS Thio, Cyrus Cooper, Eibert R Heerdink, Hubert GM Leufkens, Willem A Nolen, Antoine CG Egberts, Tjeerd P van Staa. (Netherlands)

4:45PM

Selective Serotonin Reuptake Inhibitors and Risk of Acute Pancreatitis: A Population-Based Case-Control Study [88]

Mette Nørgaard, Jacob Jacobsen, Christiane Gasse, Lars Pedersen, Preben B Mortensen, Henrik T Sørensen. (Denmark)

5:00PM

The Association between Antidepressant Use and Hypoglycemia in Diabetic Patients: A Nested Case-Control Study [89]

Hieronymus J Derijks, Fred HP De Koning, Eibert R Heerdink, Robert Janknegt, Olaf H Klungel, Antoine CG Egberts. (Netherlands)

** Student Award Recipient – Edlavitch Award*

5:15PM

Bayesian Propensity Score Analysis for Observational Data [84]

A Comparison of Patient Profiles of SSRI and SNRI Users [90]

Li Wei, Thomas M MacDonald. (United Kingdom)

continued on next page ⇨

AGENDA | Saturday, August 26

4:00 - 5:30PM

◀ SYMPOSIUM: What Stimulates Regulatory Action? [911] (AUD 8)

Syed R Ahmad, Gerald DalPan, June M Raine, Richard Hill, Christopher D Corsico. (United States)

5:30-6:30PM

◀ Special Interest Group - Health Services Research & Education (AUD 4)

Open to all participants

◀ 2007 Scientific Program Committee Meeting (Room 1.08)

Jean-Pierre Gregoire, Chair
Open to ISPE members.

7:30-11:30PM

◀ Evening at the Pateo Alfacinha *Sponsored by I3 Drug Safety*



From the late 1800's working people flooded into Lisbon looking for a better life. They build a new sort of town, squeezing many families into small areas, with as much privacy as possible, and with a country flavour Lisbon has never lost. Pateo Alfacinha has restored a pateo with a breath of village life and community, with its many rooms and floors linked together with the wisdom and charm of the original, and ironwork and tiles from old buildings. You will experience Portuguese music, food and wine, cheeses and other tidbits. Here you can make contact with Lisbon of hundreds of years ago. **Limited seating – registration required.**

Admission is by ticket only. Buses will shuttle from the Congress Centre and (ISPE) hotels to the Pateo Alfacinha beginning at 7:00PM. The last bus will depart from the Pateo Alfacinha at 11:30PM, passing by all hotels.

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that brings population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

- Analyzing the occurrence and distribution of diseases, including underlying disease process
- Determining the burden of illness and unmet medical need
- Exploring traditional and new risk factors for diseases

- Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug use and adverse events
- Detecting opportunities for possible new drug uses and new paths of drug development
- Understanding how genes influence disease etiology and drug safety and effectiveness

Please visit our booth at the 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management or our website at <http://epidemiology.gsk.com>, to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Developing talent through equality of opportunity, MIF/DIV.

Together we can make life better.



GlaxoSmithKline

Are you interested in registries for safety and effectiveness?

Come hear Dr. Nancy Dreyer speak on Friday, August 25 at 4:00 pm.

WEB-BASED REGISTRIES



RAPID DEVELOPMENT OF EVIDENCE

NANCY A. DREYER, MPH, PhD is Chief of Scientific Affairs for OUTCOME, a recognized leader in post-approval strategy.

OUTCOME has designed, developed and managed more than 70 post-approval studies and registries through prospective data collection with our web-based technology and integrated IVRS, PDA and paper options.

OUTCOME's studies include many of the largest and most well-recognized programs for disease outcomes and safety/risk management. Outcome is also a leader in Quality Improvement Programs and in 2004 received the Innovation Award from the Department of Health and Human Services.

With tens of thousands of sites and more than 2 million patients enrolled in studies powered by OUTCOME, OUTCOME provides the most widely used solutions in the post-approval market.



AGENDA | Sunday, August 27

8:00-9:00AM

◀ **Poster Session C Set-up** (PAV 4)

8:00-1:45PM

◀ **Exhibits** (PAV 5)

8:00-4:00PM

◀ **Speaker Ready Room/AV** (Rooms I.09 + I.14)

8:00-5:00PM

◀ **Registration** (Registration Desk/Ground Floor/Congress Centre)



9:00-10:30AM

CONCURRENT SESSIONS

◀ **SYMPOSIUM: Large Simple Trials To Evaluate the Safety and Effectiveness of Medicines [93]** (AUD 1)

Robert Reynolds, Allen Mitchell, Sybil Eng, Tom MacDonald, Gerald Faich. (United States)

◀ **Pills and Policy: Contributed Papers** (AUD 2)

Moderators: *Morten Andersen & Lokje de Jong van den Berg*

9:00AM

Equal Access to Treatment? Population-Based Follow-Up of Drugs Dispensed to Patients with Acute Myocardial Infarction in Sweden [94]

Gunilla Ringbäck Weitoft, Örjan Ericsson, Emil Löfroth, Måns Rosén. (Sweden)

9:15AM

Impact of Prior Authorization on Use of Angiotensin Receptor Blockers in U.S. Medicaid Programs [95]

Michael A Fischer, Niteesh K Choudhry, Wolfgang C Winkelmayr. (United States)

9:30AM

Impact of Restrictive Access to Clopidogrel Following Coronary Stent Implantation on Patient Health Outcomes [96]

Odile Sheehy, Jacques LeLorier, Stéphane Rinfret. (Canada)

9:45AM

Assessment of Analgesic Treatment Switch Patterns Post-Rofecoxib Withdrawal [97]

Myrthe PP Sukel, Wim G Goetsch, Susan E Borggreve, Connie Chen, Piotr Kramarz, Herve Lilliu, Ron MC Herings. (Netherlands)

10:00AM

What Therapies Have Replaced Rofecoxib? [98]

Mary Teeling, Kathleen Bennett, John Feely. (Ireland)

10:15AM

Rapid Monitoring of Changes in Drug Use Following Drug Policy Changes [99]

Colin R Dormuth, Sebastian Schneeweiss. (Canada)

◀ **Neurological: Contributed Papers**

(AUD 3 & 4)

Moderators: *Susan Oliveria & Michael Lewis, FISPE*

9:00AM

Migraine and the Risk of Stroke, Asthma or Death in the United Kingdom [112]

Claudia Becker, Gunnar Brobert, Per Almqvist, Saga Johansson, Susan S Jick, Christoph R Meier. (Switzerland)

9:15AM

The Impact of Visual Impairment on the Risk of Depression and Mortality in the Quebec Community-Dwelling Elderly Population [113]

Yola Moride, Marie Tournier, Ducruet Thierry, Sophie Rochon, Andriy Moshyk. (Canada)

9:30AM

Thiazolidinedione Use Is Associated with Lower Incidence of Alzheimer's Disease [560]

Donald R Miller, Benjamin G Fincke, Julie E Davidson, John G Weil. (United States)

9:45AM

Amyloid b42-Level Lowering Non-Steroidal Anti-Inflammatory Drugs and the Risk of Alzheimer's Disease [115]

Mendel DM Haag, Marieke van Oijen, Frank Jan de Jong, Albert Hofman, Theo Stijnen, Bruno HCh Stricker, Monique MB Breteler. (Netherlands)

10:00AM

Overuse of Triptans and Ergotamine and the Risk of Vasoconstrictive Complications [116]

Elisabeth A Wammes-van der Heijden, Hamid Rahimtoola, Hubert GM Leufkens, Cees C Tijssen, Antoine CG Egberts. (Netherlands)

10:15AM

The Concurrent Use of Cholinesterase Inhibitors and Contraindicated Medications in Patients with Alzheimer's Disease [117]

Alison L Supina, Amuah E Joseph, Maxwell J Colleen, Hogan B David. (Canada)

AGENDA | Sunday, August 27

◀ Stat Ins or Stat OUT: Contributed Papers (AUD 6)

Moderators: *Kate Lapane, FISPE & Olaf Klungel*

9:00AM

Is Statin Therapy Associated with a Decreased Risk for Bleeding in Patients with Chronic Atrial Fibrillation Who Are Receiving Warfarin? A Population-Based Nested Case-Control Study [I00]

James D Douketis, Magda Melo, Chaim Bell, Muhammad M Mamdani. (Canada)

9:15AM

Statin Therapy and Reduced Risk of Pneumonia in Elderly Patients with Diabetes [I01]

Ewoudt MW van de Garde, Eelko Hak, Patrick C Souverein, Arno W Hoes, Jules MM van den Bosch, Hubert GM Leufkens. (Netherlands)

9:30AM

Lipid-Modifying Therapy and attainment of Cholesterol Goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) Study. [I02]

Eric Van Ganse, Thierry Souchet, Laurent Laforest, Evo Alemao, Glenn Davies, Stephen Gutkin, Don Yin. (France)

9:45AM

Are All Statins Created Equal? An Analysis of Acute Coronary Syndrome Patients in Medicare [I03]

Nitesh K Choudhry, Raisa Levin, Wolfgang C Winkelmayr. (United States)

10:00AM

The Effect of Statins on Urinary Albumin Excretion (UAE) and Glomerular Filtration Rate (GFR): An RCT and an Observational Cohort Study [I04]

Jarir Atthobari, Auke H Brantsma, Ron T Gansevoort, Sipke T Visser, Paul E de Jong, Lolkje TW de Jong-van den Berg. (Netherlands)

10:15AM

Statin Use in Canada: Association with Lifestyle Risk Factors and Pre-Existing CVD or Diabetes [I05]

C Ineke Neutel, Norm RC Campbell. (Canada)

◀ Adherence and Switching: Contributed Papers (AUD 8)

Moderators: *Judith Jones, FISPE & John Urquhart, FIPSE*

9:00AM

Impact of Once-Weekly Bisphosphonates on Persistence Rate and Adherence Level with Osteoporosis Therapies for Secondary Prevention [I06]

Julie Blouin, Alice Dragomir, Louis-Georges Ste-Marie, Julio Cesar Fernandes, Sylvie Perreault. (Canada)

9:15AM

Evaluation of Treatment Switching Patterns in Depression: A GPRD-Based Study [I07]

Delphine Saragoussi, Sebastien Bineau, Nicolas Despiegel, Dominique Milea, Mondher Toumi, Patrice Verpillat. (France)

9:30AM

Time to Insulin after Failure of Oral Antidiabetic Therapy in Type 2 Diabetes: A UK Population-Based Analysis [I08]

Annalisa Rubino, Lisa McQuay, Marion Kvasz, Pat Tennis. (United Kingdom)

9:45AM

Changes in Antihypertensive Drug Use Following Educational Interventions in Primary Care [I09]

Sheena O'Riordan, Fiona E Horn, Judith M Mackson, Sonia E Wutzke, John Mandryk, Lynn M Weekes. (Australia)

10:00AM

Adherence to Statin Therapy under Drug Cost-Sharing in Patients with and without Acute MI: A Population-Based Natural Experiment [I10]

Sebastian Schneeweiss, Mandy Patrick, Malcolm Maclure, Colin Dormuth, Robert Glynn. (United States)

10:15AM

The Effects of Adherence on Anticoagulation Control with Warfarin [I11]

Stephen E Kimmel, Zhen Chen, Maureen Price, Catherine S Parker, Joshua P Metlay, Jason D Christie, Colleen M Brensinger, Craig W Newcomb, Frederick F Samaha, Robert Gross. (United States)

10:30-11:00AM

◀ Break/Posters/Exhibits (PAV 4/5)

11:00 - 12:30 PM

CONCURRENT SESSIONS

◀ SYMPOSIUM: Do Exclusion Criteria in

Pharmacoepidemiological Studies Matter? [118] (AUD 1)

Michael J Perrio, Patrick C Waller, Thomas M MacDonald, Kenneth J Rothman, Saad AW Shakir. (United Kingdom)

◀ Drug Utilization Research, Methods, Findings and Implications: Contributed Papers (AUD 2)

Moderators: *Lynn A. Bosco & Ulf Bergman, FISPE*

11:00AM

Differences in Secondary Medical Prevention among Danish Patients with Peripheral Arterial Disease and Myocardial Infarction: A Population-Based Follow-Up Study [119]

Christiane Gasse, Jacob Jacobsen, Henrik T Sørensen, Erik B Schmidt, Anders C Larsen, Niels Johansen, Jørgen Videbæk, Søren P Johnsen. (Denmark)

11:15AM

Cardioprotective Drug Treatment of Elderly Type 2 Diabetics in Quebec: A Population-Based Utilization Review [120]

Caroline Sirois, Jocelyne Moisan, Jean-Pierre Gregoire. (Canada)

11:30AM

Temporal Trends in Cardiovascular Drug Use after Myocardial Infarction in the Elderly [121]

Soko Setoguchi, Jerry Avorn, Robert J Glynn, Wolfgang C Winkelmayr. (United States)

11:45AM

Factors Associated with COX-2 Usage Patterns: A Multinomial Analysis in the CADEUS Study [122]

Jeremy Jove, Jacques Benichou, Fanny Depont, Cecile Droz, Michel Amouretti, Patrick Blin, Nicholas Moore, Annie Fourrier, The CADEUS Study Team. (France)

12:00PM

Face to Face Interaction between Pharmaceutical Sales Representatives and General Practitioners: Impact on Prescribing Patterns [123]

Jens Søndergaard, Kirstin Vach, Jakob Kragstrup, Morten Andersen. (Denmark)

12:15PM

Comparison of Patient Interviews and Computerized Database for Determination of Drug Exposure in Pharmacoepidemiology: Data from the "Three-City" (3C) Study [124]

Pernelle Noize, Nicholas Moore, Nathalie Lechevallier-Michel, Annie Fourrier-Reglat, The 3C Study Group. (France)

◀ Public Health Implications:

Contributed Papers (AUD 3 & 4)

Moderator: *M Levy*

11:00AM

Clinical Consequences of Drug Benefit Limits [137]

John Hsu, Maggie Price, Richard Brand, Joseph Newhouse, Joseph Selby, Rita Hui, Jie Huang, Vicki Fung, Bruce Fireman. (United States)

11:15AM

A Database for Pharmacoepidemiologic Research in Portugal [138]

Zilda Mendes, José Pedro Guerreiro, Sofia Crisóstomo. (Portugal)

11:30AM

Patterns of Medication Use in U.S. Adults and Children, 2005: A Report from the Slone Survey [139]

David W Kaufman, Judith P Kelly, Lynn Rosenberg, Theresa E Anderson, Katherine Kelly, Allen A Mitchell. (United States)

11:45AM

Patient, Physician, Pharmacy and Pharmacy Benefit Design Factors Related to Generic Medication Use [140]

William H Shrank, Margaret Stedman, Susan Ettner, Dee Delapp, June Dirstein, Alan Brookhart, Michael Fischer, Jerry Avorn, Steven Asch. (United States)

12:00PM

Determinants of Hormone Replacement Therapy in Portuguese Women [141]

Raquel Lucas, Henrique Barros. (Portugal)

12:15PM

Effect of Restricted Access to Clopidogrel on Patient Health Outcomes Following Cerebrovascular Event in the Elderly [142]

Odile Sheehy, Stéphane Rinfret, Élisabeth Leroux, Jacques LeLorier. (Canada)

◀ COX-2 and Cardiovascular Events:

Contributed Papers (AUD 6)

Moderators: *Mirjam CJM Sturkenboom & Jacques LeLorier, FISPE*

11:00AM

Association between Cyclooxygenase-2 Selective Non-Steroidal Anti-Inflammatory Drugs and Acute Myocardial Infarction in the General Practice Research Database: Preliminary Findings [125]
Tarek A Hammad, David Graham, Judy Staffa, Cynthia Kornegay, Gerald Dal Pan. (United States)

11:15AM

COX-2 Selective and Non-Selective NSAIDs and the Risk of Acute Myocardial Infarction [126]
Frank Andersohn, Samy Suissa, Edeltraut Garbe. (Germany)

11:30AM

Cox-2 Inhibitors, Other NSAIDs, and the Risk of Myocardial Infarction in Three Populations in Three Countries (UK, Canada, and the US) [127]
Michael A Lewis, Donald R Miller, Elham Rahme, Dörthe Kühl-Habich, Fran Cunningham, Amir A Tahami Monfared, David W Kaufman, Lynn Rosenberg, Jaques LeLorier. (Germany)

11:45AM

Variability of Cardiovascular Risk in Observational Studies of Nonsteroidal Antiinflammatory Drugs (NSAIDs): The Role of Calendar Time Bias [128]
Linda L Levesque, James M Brophy, Bin Zhang. (Canada)
* *Student Award – Best Methods Abstract*

12:00PM

Concomitant Aspirin Use Reduces Acute Myocardial Infarction Risk in Cyclooxygenase-2 Selective and Non-Selective Nonsteroidal Anti-Inflammatory Drug Users [129]
David J Graham, Gurkirpal Singh, Huijian Wang, Alka Mithal, George Triadafilopoulos. (United States)

12:15PM

Risks and Benefits of COX-2 Inhibitors Versus Non-Selective NSAIDs: Does Their Cardiovascular Risk Exceed Their Gastrointestinal Benefit? [130]
Elham Rahme, Hacene Nedjar. (Canada)



We Innovate Healthcare

◀ Cancer Risk, Prevention and Treatment: Contributed Papers

(AUD 8)

Moderators: *Nuno Lunet & Susan Sacks, FISPE*

11:00AM

Treatment-Related Risk Factors for Premature Menopause Following Hodgkin's Lymphoma [I31]

Marie L De Bruin, Jeannine Huisbrink, Berthe M Aleman, Floor E van Leeuwen. (Netherlands)

11:15AM

The Risk of Cancer with Antidiabetic Agents: Evidence from Clinical Trial and Observational Data [I32]

Carol E Koro, Susan A Oliveria, Marianne Ulcickas Yood, Margaret O Sowell, Monika Stender. (United States)

11:30AM

The Effect of Warfarin Use on the Risk of Urogenital Cancer [I33]

Vicky Tagalakis, Hani Tamim, Jean-Paul Collet, Susan R Kahn, Mark Blostein, James A Hanley. (Canada)

11:45AM

Long-Term NSAID Use and CYP2C9 Variant Alleles Protect Against Colorectal Cancer [I34]

Claire Siemes, Loes E Visser, Jan-Willem W Coebergh, Ron HN van Schaik, Albert Hofman, Huib AP Pols, Bruno HCh Stricker. (Netherlands)

12:00PM

Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis [I35]

Felix M Arellano, Charles E Wentworth, Alejandro Arana, Carlos Fernandez, Carle Paul, Felix M Arellano, Carle Paul. (United States)

12:15PM

History of Depression Predicts Early Discontinuation of Tamoxifen [I36]

Thomas I Barron, Kathleen Bennett, John Feely. (Ireland)

12:30-2:00PM

◀ Lunch/Poster Session C/Exhibits

(PAV 4/5)

◀ ISPE Board of Directors Luncheon

(Hotel Vila Gale Opera)

-By Invitation

2:00-3:00pm

INVITED PLENARY (AUD 1)

Henrique de Barros, *Managing Drug Risks in Public Health*

3:00-4:30pm

HOT TOPICS SESSION (AUD 1)

◀ More Science and Less Regulatory Compliance in Postmarketing Safety

Chair: Brian Strom, FISPE

June Raine, *Is Science Driving Regulatory Action, or ...?*

David Graham, *Can We Respond to All Safety Issues with a Series of Formal Pharmacoeconomic Studies?*

Andy Stergachis, FISPE, *The IOM Report: Can We Expect More Science?*

4:30-5:00PM

◀ The Final Word (PAV 1)

Jean-Pierre Gregoire,

Chair, 2007 Scientific Program Committee

5:00PM

◀ Adjournment of ICPE 2006